drugset / Trial / NCT01211405

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405 ↗

Phase 2 Completed 26 enrolled Resilient Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective and reducing PTSD symptoms in veterans with chronic PTSD. The main question it aims to answer is: Do three doses of MDMA reduce PTSD symptoms? Researchers will compare 30, 75, and 125 mg of MDMA HCl with therapy to see which dose best reduces PTSD symptoms. Participants will undergo three preparatory non-drug therapy sessions with a male and female co-therapist team, then undergo three day-long MDMA-assisted therapy sessions after receiving an initial dose of 30, 75, or 125 mg MDMA HCl. After each MDMA-assisted therapy session, participants will undergo three integrative therapy sessions.

Timeline

Start
2010-11-10
Primary completion
2015-06-04
Completion
2016-08-02

Outcome

Met primary endpoint

paper At the primary endpoint, the 75 mg and 125 mg groups had significantly greater decreases in PTSD symptom severity PMID 29728331 ↗

paper than the 30 mg group (-11·4 [12·7]). PMID 29728331 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject MDMA Unknown 30 mg Oral
Subject MDMA Unknown 75 mg Oral
Subject MDMA Unknown 125 mg Oral